SYK and rheumatoid arthritis: Tyrosine kinase-inhibitors (TKI), including Spleen tyrosine kinase (SYK) (fostamatinib) and Janus kinases (tofacitinib), are two novel oral therapies that have demonstrated good short-term clinical responses in active rheumatoid arthritis patients [43].